Engineering News

Canada approves GW Pharma cannabis drug
Tue Apr 19, 2005 06:48 AM ET

LONDON, April 19 (Reuters) - GW Pharmaceuticals Plc's cannabis-based medicine Sativex has been approved in its first market, Canada, the British biotechnology company said on Tuesday.

The go-ahead had been expected after Canadian regulators said last December that Sativex qualified to be considered for approval, but the news still boosted GW shares by 12 percent, reflecting the importance of the product to the firm.

The medicine, which is designed to help patients with multiple sclerosis and is administered by means of a spray into the mouth, will be marketed in Canada by Germany's Bayer AG.

Source: Reuters

Engineering News Archive

 
// CAREER RESOURCES

Applicant Procedures
Job Seekers
Resume Help
Professional Organizations
Engineering Career Information
Engineering Colleges

// WHAT WE DO
Recruiters for
Professionals in the Chemical
& Pharmaceutical Industries
We recruit exclusively for Engineers and Operations/Maintenance Management Personnel in the following areas:
Specialty chemicals
Bulk chemicals
Commodity Chemicals
Petrochemicals
Fine chemicals
Agrochemicals
Industrial gases
Surfactants
Fertilizers
Solvents
Coatings
Polymers
Pharmaceuticals
Refinery
Career Center | FAQs | Privacy
SESI Corporate Headquarters (954)755-3121 ext 109
© Search Enterprises, Inc. All rights reserved.
Industry News Career Center FAQs Submit a Job About Search Enterprises Submit a Resume Candidates Job Opportunities Search Enterprises Home